---
title: "Weekly Recap | Liquidia Tech -4.4%, investigations and insider sales"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301468604.md"
description: "LQDA.US fell 4.4% this week to close at $27.38, while the S&P 500 added 1.15%, leaving the stock about 5.55 percentage points behind the benchmark. The daily bars show a wide trading range: Monday opened higher before a slide, Wednesday hit the week’s low at $24.59, Thursday rebounded to $29.35, and Friday settled back at $27.38. The weekly amplitude came to 16.96%."
datetime: "2026-10-10T06:59:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301468604.md)
  - [en](https://longbridge.com/en/news/301468604.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301468604.md)
generator: "portal-rs"
---

# Weekly Recap | Liquidia Tech -4.4%, investigations and insider sales

## The Week

LQDA.US fell 4.4% this week to close at $27.38, while the S&P 500 added 1.15%, leaving the stock about 5.55 percentage points behind the benchmark. The daily bars show a wide trading range: Monday opened higher before a slide, Wednesday hit the week’s low at $24.59, Thursday rebounded to $29.35, and Friday settled back at $27.38. The weekly amplitude came to 16.96%.

## Key Events

The week centred on patent and investigation developments. Early on, two reports flagged patent remedy risk and a 6.1% price drop after an analyst downgrade. Levi & Korsinsky and SueWallSt then each issued shareholder investigation notices related to potential securities claims. Thursday brought insider selling into focus, with director Stephen M. Bloch offloading 235,477 shares worth $6.39 million, while SBS Law also launched a fraud investigation. On Friday, one article suggested the stock could be 71% undervalued on patent ruling risk. The company itself had no product approvals or earnings updates during the week.

## Analyst Ratings

Coverage totals 8 institutions: 2 rate it buy, 2 overweight, and 4 hold, with none at underweight or sell. The consensus rating is buy, and the consensus target of $49.33 sits about 80.18% above the spot price. Targets range widely from $30 to $72. Within the 203-stock pharmaceutical group, Liquidia ranks 61st in analyst rating strength.

## The Week Ahead

Next week starts with US macro releases: NFIB small business optimism and existing home sales on Tuesday, followed by CPI and core CPI on Wednesday. For Liquidia these mainly work through overall sentiment, with no company-specific earnings or major events on the calendar. Growth-name price action after the CPI prints may be the key thing to watch.

## In Short

This week the share price move and the news flow pointed in different directions: the stock slid with a wide range, while multiple shareholder investigations and insider selling added to patent uncertainty. Meanwhile, most institutions give it a buy or overweight rating, and the consensus target is well above spot. The tension now sits between a rich valuation and unresolved legal risk, with upcoming macro data as the next external driver.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [LQDA.US](https://longbridge.com/en/quote/LQDA.US.md)

## Related News & Research

- [Liquidia (NASDAQ:LQDA) Upgraded to "Outperform" at Lifesci Capital](https://longbridge.com/en/news/301888223.md)
- [Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA)](https://longbridge.com/en/news/300970598.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Alphabet Inc. $GOOG Stock Sold by Axxcess Wealth Management LLC](https://longbridge.com/en/news/302979783.md)
- [Docusign Inc. $DOCU Shares Sold by Andrew Hill Investment Advisors Inc.](https://longbridge.com/en/news/302957583.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**